Gregory R. Friberg, Executive Vice President and Chief R&D Officer of BioMarin Pharmaceutical Inc., filed a Form 4 on November 19, 2026, disclosing the sale of 5,147 shares of common stock on November 18, 2026.

Key Highlights

  • Reporting person: Gregory R. Friberg, EVP and Chief R&D Officer of BioMarin Pharmaceutical Inc.
  • Transaction: Disposition (code S) of 5,147 shares of common stock on November 18, 2026.
  • Weighted average price: $58.813 per share, with actual sale prices ranging from $58.77 to $58.855.
  • Remaining holdings: 42,585 shares of common stock held directly following the transaction.
  • Exchange and ticker: NASDAQ:BMRN.

BioMarin Chief R&D Officer Friberg Discloses November 18 Common Stock Sale

According to the filing, Gregory R. Friberg, who serves as Executive Vice President and Chief R&D Officer at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), disposed of 5,147 shares of the company's common stock on November 18, 2026. The transaction was recorded under code "S," indicating an open-market sale. The filing reports a weighted average sale price of $58.813 per share.

The filing notes in its explanation of responses that the $58.813 figure is a weighted average, and that the prices at which shares were actually sold ranged from $58.77 to $58.855. The filing further states that Friberg "shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price." Following this transaction, Friberg's direct beneficial ownership in BioMarin common stock stands at 42,585 shares, according to the filing.

No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Tae Sang Yoo as Attorney-in-Fact on November 19, 2026, and was filed as an individual, single-reporting-person submission. The filing does not indicate whether the transaction was made pursuant to a Rule 10b5-1 trading plan, as the corresponding checkbox on the form was not checked.

What Was Disclosed

The filing disclosed that BioMarin's EVP and Chief R&D Officer, Gregory R. Friberg, sold 5,147 shares of common stock on November 18, 2026, at a weighted average price of $58.813, leaving him with 42,585 shares held directly.